Ionis Pharmaceuticals (IONS) Projected to Release Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is expected to post its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of ($1.0810) per share and revenue of $189.0960 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.29. The firm had revenue of $246.09 million for the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The company’s revenue was up 86.4% on a year-over-year basis. During the same period last year, the firm earned ($0.93) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Price Performance

Ionis Pharmaceuticals stock traded down $0.82 during mid-day trading on Tuesday, hitting $55.14. The stock had a trading volume of 651,864 shares, compared to its average volume of 2,411,948. Ionis Pharmaceuticals has a one year low of $40.03 and a one year high of $86.74. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75. The firm has a market capitalization of $9.11 billion, a P/E ratio of -26.63 and a beta of 0.36. The firm’s 50 day moving average is $71.27 and its 200 day moving average is $75.31.

Analysts Set New Price Targets

Several brokerages have recently commented on IONS. Bank of America boosted their price objective on Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Oppenheimer reissued an “outperform” rating and set a $111.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, April 30th. HC Wainwright reissued a “buy” rating on shares of Ionis Pharmaceuticals in a report on Thursday. Morgan Stanley cut their price objective on shares of Ionis Pharmaceuticals from $130.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, July 10th. Finally, Needham & Company LLC lowered their target price on shares of Ionis Pharmaceuticals from $105.00 to $86.00 and set a “buy” rating on the stock in a report on Thursday, July 9th. Eighteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.90.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eugene Schneider sold 26,000 shares of Ionis Pharmaceuticals stock in a transaction on Friday, June 26th. The shares were sold at an average price of $81.05, for a total value of $2,107,300.00. Following the completion of the transaction, the executive vice president directly owned 77,114 shares of the company’s stock, valued at $6,250,089.70. This trade represents a 25.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP C Frank Bennett sold 15,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $85.46, for a total transaction of $1,281,900.00. Following the completion of the sale, the executive vice president owned 75,018 shares in the company, valued at approximately $6,411,038.28. This trade represents a 16.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 233,163 shares of company stock valued at $18,316,551 in the last 90 days. Company insiders own 1.81% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brown Brothers Harriman & Co. purchased a new stake in Ionis Pharmaceuticals during the fourth quarter valued at approximately $27,000. Quarry LP bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $38,000. Johnson Financial Group Inc. purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at $44,000. Los Angeles Capital Management LLC bought a new stake in Ionis Pharmaceuticals in the fourth quarter worth $52,000. Finally, Summit Securities Group LLC bought a new stake in Ionis Pharmaceuticals in the fourth quarter worth $59,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.